Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O'Shea, Leo I. Gordon, Jane N. Winter*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds